Entera Bio (ENTX) Research & Development (2019 - 2026)
Entera Bio's (ENTX) quarterly Research & Development came in at $2.3 million in Q1 2026, up 100.45% YoY from $1.1 million in Q1 2025, and up 31.02% on a QoQ basis from $1.7 million in Q4 2025.
Entera Bio (ENTX) Research & Development (2019 - 2026) Analysis & Trends
Entera Bio (ENTX) has 8 years of Research & Development data on file, last reported at $2.3 million in Q1 2026.
- Quarterly Research & Development rose 100.45% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 million (up 45.94% YoY) and the FY2025 annual result came in at $6.0 million, up 33.45% from the prior year.
- Research & Development grew to $2.3 million in Q1 2026, from $1.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $2.3 million in Q1 2026 to a low of $735000.0 in Q1 2024.
- A 5-year average of $1.4 million and a median of $1.4 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development sank 49.0% — and 2026, when it soared 100.45%.
- Tracing ENTX's Research & Development over 5 years: stood at $1.4 million in 2022, then slipped by 25.98% to $1.0 million in 2023, then rose by 20.1% to $1.2 million in 2024, then surged by 43.05% to $1.7 million in 2025, then surged by 31.02% to $2.3 million in 2026.
- The last three Research & Development figures came in at $2.3 million (Q1 2026), $1.7 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 97.90 Mn |
| 10 | Entera Bio | 166.99 Mn | 155.68 Mn | - | 3.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.20 Mn |
| Mar 31, 2026 | 2.25 Mn |
| Dec 31, 2025 | 1.72 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Mar 31, 2025 | 1.12 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.48 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 735,000.00 |
| Dec 31, 2023 | 1.00 Mn |
| Sep 30, 2023 | 1.37 Mn |
| Jun 30, 2023 | 1.21 Mn |
| Mar 31, 2023 | 931,000.00 |
| Dec 31, 2022 | 1.35 Mn |
| Sep 30, 2022 | 1.41 Mn |
| Jun 30, 2022 | 1.39 Mn |
| Mar 31, 2022 | 1.69 Mn |
| Dec 31, 2021 | 2.65 Mn |
| Sep 30, 2021 | 1.77 Mn |